Research Roundup: prognostic biomarkers in cancer

Many of our cancer antibodies are used in cutting-edge research to identify new prognostic markers in different cancers. Let's take a look at three recent studies.

Antibody-based biomarker discovery can lead to more accurate diagnosis and a better assessment of patient prognosis, ultimately improving outcomes for cancer patients around the world.

The following three studies have all successfully utilized different Atlas Antibodies products in their research.

Read on to see our antibodies in action!

1. Validation of novel prognostic biomarkers for early-stage clear-cell endometrioid and mucinous ovarian carcinomas using immunohistochemistry (Engqvist et al. 2020)

Some early-stage ovarian cancer patients die unexpectedly and much earlier than expected. It’s therefore important to stratify these patients into risk groups to identify those in need of more aggressive treatment regimens.

This new study is important in validating 17 novel histotype-specific biomarkers for three of the major histotypes of early-stage ovarian cancer: clear cell ovary carcinoma, endometrioid and mucinous ovary carcinomas. These markers have not been connected with the prognosis of these histotypes before.

In this study, 11 polyclonal antibodies from Atlas Antibodies were used. 

Linked Antibodies:

Figure 1. Example of Atlas Antibodies Anti-DDX24 (HPA002554) staining. Left: IHC staining of human testis shows strong nuclear positivity in cells in seminiferous ducts, in brown. Right: ICC-IF staining of human cell line U-2 OS shows positivity in nucleoli and cytoplasm in green. Microtubules in red. Nuclei in blue.

Reading tip: The Pathology Atlas - a discovery journey in cancer research.


2. The value of desmosomal plaque-related markers to distinguish squamous cell carcinoma and adenocarcinoma of the lung (Galindo et al. 2020)

Lung carcinomas can be difficult to manage and are often challenging to diagnose histologically. 

This new study provides an addition to the arsenal of IHC panel biomarkers able to distinguish between aggressive, difficult to diagnose forms of lung cancer by demonstrating PKP1 as a marker of prognostic value.

Two of the primary antibodies used in this study: rabbit anti-human PKP-1 (HPA027221) and rabbit anti-human KRT15 (HPA024554) were from Atlas Antibodies.

Linked antibodies:


Figure 2. Example of Atlas Antibodies Anti-PKP1 (HPA027221) staining. Left: WB analysis in human cell lines PC-3 and A-549 using Anti-PKP1 antibody. Corresponding PKP1 RNA-seq data are presented for the same cell lines. Loading control: Anti-PPIB. Right: ICC-IF staining of human cell line PC-3 shows localization to nucleoplasm & plasma membrane in green. Microtubules in red.

3. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2: ERG fusion (Fraune et al. 2020)

Nuclear transcription factor TFDA2 is upregulated in genomically unstable prostate tumors and associated with poor patient prognosis.

The study authors found that that TFAP2D expression was typically increased in prostate cancer as compared to adjacent non-neoplastic glands and identified TFDA2 as a novel IHC-marker, which together with other markers, could be utilized to obtain a more accurate diagnosis of aggressive prostate cancers.

Linked antibodies:

Figure 3. Example of Atlas Antibodies Anti-TFAP2D (HPA048962) staining.Left: IHC staining of the human cerebral cortex shows moderate nuclear and cytoplasmic positivity in neuronal cells, in brown.Right: ICC-IF staining of human U-2 OS cell line shows localization in the nucleoplasm, Golgi apparatus, and vesicles, in green. Microtubules in red.